Clinical observation of alprostadil combined with cilostazol in treatment of lower limb atherosclerosis
10.3760/cma.j.issn.1673-4904.2012.07.010
- VernacularTitle:前列地尔联合西洛他唑治疗下肢动脉粥样硬化症临床观察
- Author:
Wenjin HE
;
Fan LIU
;
Shi YANG
- Publication Type:Journal Article
- Keywords:
Alprostadil;
Cilostazol;
Lower limb atherosclerosis
- From:
Chinese Journal of Postgraduates of Medicine
2012;35(7):29-31
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the curative effect of alprostadil combined with cilostazol in treatment of patients with lower limb atherosclerosis.MethodsSixty-two patients with lower limb atherosclerosis were divided into cilostazol group (cilostazol 100 mg,2 times a day,oral) and therapeutic alliance group (cilostazol 100 mg,2 times a day,oral; alprostadil 10 μ g dissolved in 100 ml intravenous infusion of 0.9％ sodium chloride,once a day) by random number table with 31 cases each.The changes of ankle-brachial index (ABI),distance of 6-minute walk test(6-MWT) and the dorsal blood flow were compared before and after treatment.Results | After treatment,the distance of 6-MWT,ABI and the level of dorsal blood flow were significantly improved in two groups (P ＜ 0.05 or ＜ 0.01 ).Distance of 6-MWT and the level of dorsal blood flow in therapeutic alliance group was significantly higher than that in cilostazol group after treatment [(425.4±138.5) m vs.(379.5±124.6) m,(0.77±0.18) ml/ (s·cm2) vs.(0.66±0.14) ml/( s· cm2)] ( P＜0.05 ).The total effective rate in the treatment of cold feel in therapeutic alliance group was significantly higher than that in cilostazol group [ 87.5％(21/24) vs.61.9％( 13/21 ) ](P＜ 0.05).Conclusion Alprostadil combined with cilostazol is safe and effective in treating lower limb atherosclerosis.
